title: Bcl-2, cell cycle regulatory proteins and corticosensitivity in childhood acute lymphoblastic leukaemia.
abstract: The results of treatment in childhood acute lymphoblastic leukemia (ALL) remain incompletely satisfactory because of relapses observed even with high dose chemotherapy. The aim of this study was to evaluate the role of bcl-2 or cell cycle regulatory protein expression in peripheral blood cells before and during the first 48 hours of corticotherapy, and corticosensitivity criteria for predicting relapse and prognosis. Fifty two children presenting with ALL were studied at diagnosis and during the first 48 hours of treatment for the level of cell proliferation by measurement of DNA content, and for expression of several cell proliferation regulatory proteins by Western blot. Two criteria for corticosensitivity were used: 1--the number of blast cells present after seven days of treatment with a threshold at 1 G/L (usual criterion), 2--the D8/D1 blast cell ratio, which is independent of the initial leucocytosis. Relapse in the total patient population or in B-cell ALL could only be predicted by the level of leucocytosis before treatment or by p27kip1 expression during the first 48 hours of treatment. Disease free survival was significantly longer when the D8/D1 blast cell ratio was under the 0.75 quartile in the entire patient population (p = 0.03). Among the proteins analyzed, bcl-2 expression before treatment and p27kip1 expression analyzed after 48 hours of corticotherapy were the sole variables associated with significant differences in disease free survival duration in the entire patient population (p < 0.01 and p = 0.04 respectively) or in the B-cell ALL subgroup (p < 0.01). Comparable results were obtained for the overall survival data. The significance of these results is discussed but such a study on blood blast cells needs to be validated in a larger series.
authors.affiliation: Laboratoire de Cytologie Analytique, Université Claude Bernard, Unité INSERM U453, Lyon, France.
authors.forename: N
authors.initials: N
authors.lastname: Baghdassarian
authors.forename: Y
authors.initials: Y
authors.lastname: Bertrand
authors.forename: L M
authors.initials: LM
authors.lastname: Gerland
authors.forename: P
authors.initials: P
authors.lastname: Ffrench
authors.forename: P
authors.initials: P
authors.lastname: Duhaut
authors.forename: P A
authors.initials: PA
authors.lastname: Bryon
authors.forename: J P
authors.initials: JP
authors.lastname: Magaud
authors.forename: M
authors.initials: M
authors.lastname: Ffrench
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000494:pharmacology*; D002453:Cell Cycle; D018797:Cell Cycle Proteins / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D007223:Infant; D007964:Leukocytosis; D008297:Male; D015999:Multivariate Analysis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D011239:Prednisolone / Q000008:administration & dosage / Q000494:pharmacology; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D012008:Recurrence; D016019:Survival Analysis
chemical_list: D000305:Adrenal Cortex Hormones; D018797:Cell Cycle Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D011239:Prednisolone